
News|Articles|November 15, 2021
SterRx Recalls 240 Lots of 12 Products
Equipment and process issues could lead to a lack of sterility.
Advertisement
SterRx is recalling about 240 lots of 12 different products. The recall is being made because of due equipment and process issues that could lead to a lack of sterility. To date, SterRx has not received reports of adverse events associated.
These lots were distributed between December 2020 and October 2021.
The products impacted include:
- 1mg/mL Midazolam in 0.9% Sodium Chloride
- Fentanyl in 0.9% Sodium Chloride
- 1mg/mL Morphine Sulfate in 0.9% Sodium Chloride
- 1mg/mL Morphine Sulfate in 5% Dextrose
- 125mg Diltiazem HCL in 0.7% Sodium Chloride
- 125mg Diltiazem HCL in 5% Dextrose
- Norepinephrine in 0.9% Sodium Chloride
- Norepinephrine in 5% Dextrose
- Epinephrine in 0.9% Sodium Chloride
- Phenylephrine in 0.9% Sodium Chloride
- 150mEq Sodium Bicarbonate in 5% Dextrose
- 200mg Succinylcholine Chloride in 0.9% Sodium Chloride
Those with questions should call (518) 324-7983 or email
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Retatrutide shows substantial weight loss, glycemic control in obesity and type 2 diabetes | ADA 2026
2
CONNECT data support CGM use in non-insulin type 2 diabetes management | ADA 2026
3
Pivotal trial is recruiting for monthly GLP-1 for weight loss | ADA 2026
4
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
5






























